Clearmind Medicine Files Interim Financials for July 31, 2025
Ticker: CMND · Form: 6-K · Filed: Sep 11, 2025 · CIK: 1892500
Sentiment: neutral
Topics: financial-reporting, interim-results, foreign-private-issuer
TL;DR
Clearmind Medicine dropped its Q3 financials, check 'em out.
AI Summary
Clearmind Medicine Inc. filed its unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the periods ending July 31, 2025. The filing, made on September 11, 2025, covers the three and nine months ended on that date. The company is incorporated in Canada and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides investors with an update on Clearmind Medicine's financial performance and operational status for the recent interim period, crucial for assessing the company's trajectory.
Risk Assessment
Risk Level: medium — As a foreign private issuer in the pharmaceutical sector, Clearmind Medicine faces regulatory, clinical, and market risks inherent to drug development and international operations.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the report
- July 31, 2025 (date) — End of reporting period for financial statements
- September 11, 2025 (date) — Date of filing
- Vancouver, British Columbia (location) — Company's principal executive offices
FAQ
What period do the unaudited financial statements cover?
The unaudited condensed interim consolidated financial statements cover the three and nine months ended July 31, 2025.
When were these financial statements filed?
These financial statements were filed on September 11, 2025.
What is Clearmind Medicine Inc.'s SIC code?
Clearmind Medicine Inc.'s Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
Where are Clearmind Medicine Inc.'s principal executive offices located?
Clearmind Medicine Inc.'s principal executive offices are located at 101 - 1220 West 6th Avenue, Vancouver, British Columbia.
Does Clearmind Medicine Inc. file annual reports under Form 20-F or 40-F?
Clearmind Medicine Inc. files annual reports under Form 20-F.
Filing Stats: 354 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2025-09-11 16:01:20
Filing Documents
- ea0256170-6k_clearmind.htm (6-K) — 17KB
- ea025617001ex99-1_clearmind.htm (EX-99.1) — 564KB
- ea025617001ex99-2_clearmind.htm (EX-99.2) — 143KB
- 0001213900-25-086821.txt ( ) — 4274KB
- cmnd-20250731.xsd (EX-101.SCH) — 63KB
- cmnd-20250731_cal.xml (EX-101.CAL) — 35KB
- cmnd-20250731_def.xml (EX-101.DEF) — 235KB
- cmnd-20250731_lab.xml (EX-101.LAB) — 428KB
- cmnd-20250731_pre.xml (EX-101.PRE) — 255KB
- ea0256170-6k_clearmind_htm.xml (XML) — 619KB
Management's Discussion and Analysis for the for the three and nine months ended July 31, 2025
Management's Discussion and Analysis for the for the three and nine months ended July 31, 2025. 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine Inc. Date: September 11, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3